We report the first two cases of posttransplant lymphoproliferative disorder (PTLD) in recipients of islet transplants worldwide. First, a 44-year-old recipient of three islet infusions developed PTLD 80 months after his initial transplantation, presenting with abdominal pain and diffuse terminal ileum thickening on imaging. He was treated with surgical excision, reduction of immunosuppression, and rituximab. Seven months later, he developed central nervous system PTLD, presenting with vertigo and diplopia; immunosuppression was discontinued, resulting in graft loss, and he was given high-dose methotrexate and underwent consolidative autologous stem cell transplantation. He remains in remission 37 months after the initial diagnosis. Second, a 58-year-old female recipient of two islet infusions developed PTLD 24 months after initial islet infusion, presenting with pancytopenia secondary to extensive bone marrow involvement. Immunosuppression was discontinued, resulting in graft loss, and she received rituximab and chemotherapy, achieving complete remission. Both patients were monomorphic B cell PTLD subtype by histology and negative for EpsteinBarr virus in tissue or blood. These cases document the first occurrences of this rare complication in islet transplantation, likely secondary to prolonged, intensive immunosuppression, and highlight the varying clinical manifestations of PTLD. Further studies are needed to determine incidence rate and risk factors in islet transplantation.
Introduction
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of immunosuppression in solid organ (SOT) and hematopoietic stem cell transplantation (HSCT), causing a high rate of mortality and graft loss (1, 2) . Histologic subtypes of PTLD range from benign lymphoid hyperplasia (i.e. early lesions) to aggressive lymphoma (i.e. monomorphic PTLD) (3) . Epstein-Barr virus (EBV) infection tends to drive the pathogenesis of early PTLD, via primary infection or reactivation of quiescent virus, but the role of EBV in PTLD occurring late posttransplantation and in monomorphic PTLD is less clear (2, 4) . The incidence of PTLD in adult SOT is highest in multivisceral and intestinal (3-7%) and lowest in renal transplants (1-3%), mainly attributed to lymphocyte load in the allograft and intensity of immunosuppression (5) (6) (7) (8) (9) (10) (11) (12) . In contrast to SOT and HSCT, no cases of PTLD have been reported to date after clinical islet transplantation despite the prolonged immunosuppression required. insulin secretion in highly selected subjects with type 1 diabetes (T1D) (13) . Since 2002, islets have been cultured for up to 48 h before transplantation, which increases islet purity due loss of exocrine cells (14) . Islet transplantation provides excellent glycemic control and robust protection from severe hypoglycemia (15) . Recipients may require more than one islet infusion (up to five at our center, each from different donors) to achieve or maintain long-term insulin independence and generally require immune conditioning therapies before each infusion. Lymphocyte-depleting induction agents, such as alemtuzumab or thymoglobulin, have become standard of care in many centers because of superior graft outcomes (16) . In contrast to the original "Edmonton Protocol," which used sirolimus for immunosuppression, our standard steroid-sparing immunosuppression regimen uses tacrolimus and mycophenolate mofetil (MMF) (17) . Antiviral prophylaxis followed by weekly monitoring or pre-emptive management is used depending on donorrecipient EBV and cytomegalovirus (CMV) serostatus and exposure to lymphodepleting agents (18) . Since 1999, 250 patients have received islet allografts at our center. Registry data report >800 islet allograft recipients worldwide with no cases of PTLD (19) . Here, we describe what we believe to be the first and second reported cases of PTLD after islet transplantation.
Case Reports
Case 1 A 44-year-old man underwent islet transplantation for longstanding T1D complicated by frequent, severe hypoglycemia with impaired awareness. He received three islet transplants (0, 13 months, and 71 months from first transplantation) and became functionally insulin independent (Table 1) . Complications included varicella meningitis before his third transplantation.
Eighty months after his initial transplantation, he presented with a 2-week history of weight loss, abdominal pain, and diarrhea with stools infrequently stained with bright blood. Blood work revealed normocytic anemia (hemoglobin 98 g/L). Computed tomography (CT) scanning showed circumferential wall thickening involving 10 cm of the terminal ileum with no bowel obstruction. Colonoscopy revealed a friable ulcerated cecal mass. He underwent a therapeutic and diagnostic right hemicolectomy.
Histological analysis of the cecal mass revealed large lymphoid cells with vesicular chromatin and high nucleus:cytoplasm ratio in a transmural growth pattern reaching the lumen of both cecum and terminal ileum ( Figure 1A,B) . In situ hybridization studies confirmed a kappa light chain restriction and negative EBV-encoded RNA (EBER). Immunohistochemistry (IHC) revealed positive CD20, a proliferation rate of 90% by MIB1 ( Figure 1C,D) , and negative CMV. The lesion was identified as PTLD, monomorphic B cell type, consistent with diffuse large B cell lymphoma (DLBCL).
Positron emission tomography (PET) scan 14 days postoperatively showed no residual disease or other systemic areas of involvement. Immunosuppression was reduced (tacrolimus target range 6-8 lg/L, MMF discontinued), and he was treated with rituximab (375 mg/m 2 IV in four weekly doses).
Seven months after PTLD diagnosis, he presented with vertigo, frontal headache, diplopia, and unsteady gait of 4 days' duration. Physical examination revealed horizontal nystagmus on right lateral gaze, but no cranial nerve deficit or motor weakness was noted. Magnetic resonance imaging (MRI) of the brain revealed multiple periventricular enhancing lesions with vasogenic edema, the largest of which was located in the posterior horn of the right lateral ventricle and measured 2.3 9 1.9 9 2.2 cm, highly suggestive of central nervous system (CNS) PTLD (Figure 2A ,B). PET-CT and bone marrow biopsy results were negative for systemic lymphoma. Plasma EBV quantitative nucleic acid test was negative. Cerebrospinal fluid (CSF) tested negative for viruses (including EBV and CMV), but cytology showed atypical lymphoid cells highly suspicious for a lymphoproliferative disorder.
Maintenance immunosuppression was discontinued, and multiple daily insulin injections were resumed. The patient received four cycles of high-dose methotrexate (HD-MTX) (3.5 g/m 2 ) in 2 months, and follow-up brain MRI demonstrated partial response. He received chemotherapy for stem cell mobilization followed by autologous stem cell transplantation (ASCT) [protocol described in (20) ]. His recovery post-ASCT was complicated by enteritis, febrile neutropenia, intravenous line-associated Propionibacterium septicemia, and acute kidney injury. His last brain MRI 28 months after CNS lymphoma diagnosis showed no evidence of relapse ( Figure 2C ). The patient is now insulin dependent with no significant residual graft function (C-peptide <0.1 nmol/L).
Case 2
A 58-year-old woman with longstanding T1D and frequent, severe episodes of hypoglycamia with impaired awareness underwent islet transplantation. Past medical history included coronary artery disease and diabetic retinopathy. A two-step tuberculin test was strongly positive, necessitating a 4-month course of rifampacin. She achieved insulin independence after two islet infusions 4 months apart. She resumed exogenous insulin 10 months later due to suboptimal glycemic control [glycated hemoglobin 7.6% (Table 1) ].
Two years after her initial transplantation, she developed pancytopenia with blast-like cells in peripheral blood (Figure 3A) , identified on flow cytometry as a clonal (i.e. kappa-restricted) mature B cell population. In the bone marrow biopsy, sheets of large cells with pleomorphic centroblastic morphology obliterated the marrow adipose architecture ( Figure 3B ). Atypical cells showed expression of CD20, 70% proliferation rate by MIB1 ( Figure 3C , D), and negative for EBER and negative for CMV on IHC. The lesion was classified as PTLD, monomorphic type (DLBCL). EBV viral load in blood was low (<500 copies/ mL). Staging CT scan identified diffuse nonbulky lymphadenopathy. Biopsy of an inguinal lymph node was attempted, but extensive necrosis severely limited pathologic assessment.
Tumor lysis syndrome (TLS) with acute kidney injury was treated with intravenous fluid and rasburicase. Maintenance immunosuppressive therapy was discontinued permanently. Chemoimmunotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone [RCHOP]) was commenced urgently in the hospital; five additional cycles of RCHOP were delivered on an outpatient basis with no complications such as infection or rehospitalization. Posttreatment PET-CT scanning showed complete metabolic response, and bone marrow biopsy showed no residual disease based on morphology and flow cytometry examinations. The patient returned to pretransplantation insulin doses and has no residual allograft function (C-peptide <0.01 nmol/L).
Discussion
This report documents the first two cases of PTLD after islet transplantation, indicating that islet recipients are at risk of this serious complication, similar to SOT recipients. We estimate the incidence rate of PTLD in islet recipients at our center, reflecting the data in this report, at 0.8% (i.e. two cases of 250 transplanted over 17 years); for recipients of two or more versus three or more islet infusions, we estimate the incidence of PTLD at 0.9% (i.e. 2/220) and 1.2% (i.e. 1/85), respectively. Low numbers of passenger lymphocytes, as a result of islet isolation and culture and the small mass of tissue transplanted (21) , may contribute to low PTLD risk in islet transplantation compared with high number of passenger lymphocytes and resultant high PTLD rates in small bowel and lung transplantations (5, 6, 9 ). The precise number of passenger leukocytes in islet preparations is unknown, but one report examining the endocrine composition of islets estimated that leukocytes comprise well below 5% (22) . Both our patients had potent induction with lymphocyte-depleting induction agents, which increases the risk of early PTLD in SOT and HSCT (5, 23) , although the risk may be lower for alemtuzumab (24) . They also had moderately intensive maintenance immunosuppression, as target levels for calcineurin inhibitors for islet transplantation at our center (8-10 ng/mL) are generally higher than those for renal transplantation but lower than those for lung transplantation. Both cases were DLBCL with no evidence of EBV or CMV occurring beyond 1 year posttransplantation, the most common histologic subtype and presentation of PTLD in SOT (8, 25, 26) . Post-SOT DLBCL shares its molecular pathogenesis with nontransplant lymphomas rather than EBV-positive PTLD (4), supporting a noninfectious etiology. We speculate that intensive immunosuppression, rather than the islets themselves, contributed to lymphomagenesis in our reported cases. Detailed epidemiologic studies are needed when more cases accrue in islet recipients. PTLDs in SOT are predominantly recipient origin (27) . Few donor lymphocytes and monomorphic, EBV-negative histology support recipient origin in our cases, but their relatively short latency time from last transplantation, particularly for case 1 (9 months), make donor origin possible. We were unable to investigate origin through molecular studies, but origin of future cases should be determined.
A B C
The current standard treatment for CD20-positive PTLD after SOT is reduction of immunosuppression (RIS) followed by sequential therapy (i.e. rituximab then RCHOP chemotherapy) (28, 29) . Patients in complete remission with rituximab alone often maintain a durable remission without chemotherapy (29) . There is support for rituximab alone in patients with an isolated bowel mass surgically excised (30) , as in our first case. Patients with aggressive presentations, such as our second case, may benefit from immediate chemoimmunotherapy (31) .
RIS was originally recommended to restore T cell response to EBV-positive PTLD (32), but its contribution to treatment in EBV-negative PTLD is unclear. Both our patients discontinued immunosuppression to improve tolerability of chemotherapy, since treatment-related mortality from chemotherapy in SOT patients can exceed 30% (33) . Because RIS in islet transplantation does not immediately lead to graft loss, RIS may be preferred over complete withdrawal when treating with rituximab alone.
Relapse of DLBCL in the CNS is rare but unfavorable and generally fatal; risk factors for CNS relapse are poorly understood in DLBCL (34) and not previously studied in PTLD. HD-MTX is an accepted treatment for fit nontransplantation patients with normal renal function, and chemosensitive patients can achieve prolonged remission with consolidative ASCT (35) . Although many transplant patients are poor candidates for these regimens due to comorbidities, SOT patients have been treated successfully with HD-MTX for CNS PTLD (36, 37) and ASCT for relapsed PTLD (38) (39) (40) . Our report represents both the first case of secondary CNS relapse of PTLD successfully treated with HD-MTX and consolidative ASCT and the first islet transplant patient with relapsed PTLD treated with ASCT.
Conclusion
Recipients of islet transplantation have a small, but finite, risk of developing PTLD, likely due to prolonged, intensive immunosuppression. As more cases accrue, epidemiologic studies of risk factors will be needed to inform islet transplantation candidate selection. Despite aggressive clinical presentations, successful treatment of PTLD in islet transplant is feasible with modalities that include RIS, surgery, rituximab, chemotherapy, and ASCT.
